Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

836
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
836
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

2.8K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.8K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Case of Anterior Cranial Fossa Dural Arteriovenous Fistula with Transient Ocular Movement Disorder after Embolization.

Journal of neuroendovascular therapy·2023
Same author

What impacts do the new ESH 2023 guidelines have on the management of hypertension in Japan?

Hypertension research : official journal of the Japanese Society of Hypertension·2023
Same author

Prediction of oxygen supplementation by a deep-learning model integrating clinical parameters and chest CT images in COVID-19.

Japanese journal of radiology·2023
Same author

The VIPR2-selective antagonist KS-133 changes macrophage polarization and exerts potent anti-tumor effects as a single agent and in combination with an anti-PD-1 antibody.

PloS one·2023
Same author

Association of cancer with the risk of developing hypertension.

European heart journal. Quality of care & clinical outcomes·2023
Same author

Future Prospects of Onco-Hypertension.

Hypertension (Dallas, Tex. : 1979)·2023

Related Experiment Video

Updated: Mar 29, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.4K

[Development trends for antihypertensive drug].

Akira Nishiyama

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |December 2, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Despite existing antihypertensive drugs, blood pressure control remains inadequate for many. New drug development, particularly targeting the renin-angiotensin-aldosterone system, is crucial for preventing cardiovascular outcomes.

    More Related Videos

    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
    05:57

    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

    Published on: May 17, 2024

    1.3K
    Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
    07:51

    Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

    Published on: September 26, 2018

    8.2K

    Related Experiment Videos

    Last Updated: Mar 29, 2026

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
    08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    4.4K
    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
    05:57

    Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

    Published on: May 17, 2024

    1.3K
    Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
    07:51

    Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

    Published on: September 26, 2018

    8.2K

    Area of Science:

    • Cardiology
    • Pharmacology
    • Nephrology

    Context:

    • Hypertension is a major risk factor for cardiovascular mortality and morbidity.
    • Current antihypertensive drug treatments provide insufficient blood pressure control in many patients.
    • Clinical trials indicate limited differentiation among antihypertensive drug classes regarding cardiovascular and renal protection beyond blood pressure lowering.

    Purpose:

    • To review current development trends in antihypertensive drugs.
    • To focus on novel agents targeting the renin-angiotensin-aldosterone system.
    • To highlight the need for improved therapeutic strategies for hypertension management.

    Summary:

    • This review examines the evolution of antihypertensive medications.
    • It emphasizes the ongoing challenge of achieving adequate blood pressure control.
    • The focus is on emerging drugs modulating the renin-angiotensin-aldosterone system.

    Impact:

    • Informs the development of next-generation antihypertensive therapies.
    • Aims to improve cardiovascular and renal outcomes in hypertensive individuals.
    • Highlights the critical need for novel pharmacological approaches to combat hypertension-related diseases.